


FIG. 1



A
d9 Tumor % Foxp3+/CD45+
Foxp3+/CD45 (%)
0
1
2
3
4
5
control
aOX40
aPDL1
combo
B
d9 Tumor: Foxp3+ total
cell number x10^4
0
50
100
150
200
250
control
OX40
PDL-1
combo

FIG. 2



A
d9 Tumor CD11b+ Gr-1lo/int:
PDL1 geo MFI
PDL1 geo MFI
20000
15000
10000
5000
0
**
control
aOX40
B
d9 Tumor CD45-
PDL1 geo MFI
PDL1 geo MFI
30000
20000
10000
0
*
control
aOX40

FIG. 3



Tumor Volume (mm3)
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
Day
aPDL1
control
aOX40
aOX40 + aPDL1
Mu IgG1 anti-gp120 10mg/kg IP TIW
Mu IgG2a anti-OX40 10mg/kg IP TIW
Mu IgG1 anti-PD-L1 6E11.1.9 WT 10mg/kg IP TIW
Mu IgG2a anti-OX40 10mg/kg IP TIW +Mu IgG1 anti-PD-L1 6E11.1.9 WT 10mg/kg IP TIW

FIG. 4A

FIG. 4B




control
aOX40
aPDL1
aOX40 + aPDL1
Tumor Volume (mm3)
Day
4096
2048
1024
512
256
128
64
32
16
8
4
10
20
30
40

FIG. 5A


Tumor Volume (mm³)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
Day
control
aPDL1
aOX40
aOX40 + aPDL1
1 – anti–gp120 tiwx3, 10mg/kg IV 1st dose, thereafter 5mg/kg IP
3 – anti–OX40 1mg/kg IV Day 1
4 – anti–PD–L1 tiwx3, 10mg/kg IV 1st dose, thereafter 5 mg/kg IP
6 – anti–OX40 1mg/kg + anti–PD–L1




control
aOX40
aPDL1
aOX40 + aPDL1
Tumor Volume (mm3)
4096
2048
1024
512
256
128
64
32
16
8
4
10
20
30
40
Day

FIG. 5B

FIG. 6A


Tumor Volume (mm3)
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
Day
aOX40, 0.01mg/kg
aOX40, 0.1mg/kg
aOX40, 1mg/kg
control
01 – Mu IgG1 anti–gp120 1306, 1 mg/kg
05 – Mu IgG2a anti–mOX40, 0.01 mg/kg, TIWx3
06 – Mu IgG2a anti–mOX40, 0.1 mg/kg, TIWx3
07 – Mu IgG2a anti–mOX40, 1 mg/kg, TIWx3




control
aOX40, 0.01mg/kg
aOX40, 0.1mg/kg
aOX40, 1mg/kg
Tumor Volume (mm3)
Day
4096
2048
1024
512
256
128
64
32
0
10
20
30

FIG. 6B

FIG. 7A


Tumor Volume (mm3)
3000
2800
2600
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
10
20
30
40
Day
control
aPDL1
aOX40
aOX40 + aPDL1
Mu IgG1 anti–gp120 10mg/kg IP TIW
Mu IgG2a anti–OX40 0.1mg/kg IP TIW
Mu IgG1 anti–PD–L1 6E11.1.9 WT 10mg/kg IP TIW
Mu IgG2a anti–OX40 0.1mg/kg IP TIW +Mu IgG1 anti–PD–L1 6E11.1.9 WT 10mg/kg IP TIW




control
aOX40
aPDL1
aOX40 + aPDL1
Tumor Volume (mm3)
Day
4096
2048
1024
512
256
128
64
32
16
8
4
10
20
30
40

FIG. 7B

FIG. 8A


Tumor Volume (mm³)
2400
2200
2000
1800
1600
1400
1200
1000
800
600
400
200
0
20
40
60
80
Day
control
aPDL1
aOX40
aOX40 + aPDL1
1 – anti–gp120 tiwx3, 10mg/kg IV 1st dose, thereafter 5mg/kg IP
2 – anti–OX40 0.1mg/kg IV Day 1
4 – anti–PD–L1 tiwx3, 10mg/kg IV 1st dose, thereafter 5 mg/kg IP
5 – anti–OX40 0.1mg/kg + anti–PD–L1



control
aOX40
aPDL1
aOX40 + aPDL1
Tumor Volume (mm³)
Day
4096
2048
1024
512
256
128
64
32
16
8
4
20
40
60
80

FIG. 8B



CT26 Peripheral Blood
A
Proliferating T cells
Ki67/CD8(%)
B
Tregs
CD4+Foxp3+/CD45 (%)
C
Plasma IFNg
IFNg (pg/ml)
D
Activated T cells
CXCR3/CD8 (%)
Control
a-OX40
a-PDL1
Combo

FIG. 9




BLADDER (Phase I)
NSCLC (Phase I)
OX40 expression (qPCR)
PDL1 IC IHC
PDL1 IC IHC
PRCR
SD
PD
IHC0
IHC1
IHC2
IHC3

FIG. 10

FIG. 11


A
Negative control
(parental 293)
B
293-PD-L1 low
C
293-PD-L1 med
D
293 PD-L1 high
Positive tissue control
E
Placenta
F
Tonsil



A
Triple-Negative Breast Cancer
B
Malignant Melanoma
C
NSCLC, adenocarcinoma

FIG. 12